Focused On-demand Library for Large ribosomal subunit protein uL29m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9HD33

UPID:

RM47_HUMAN

Alternative names:

39S ribosomal protein L47, mitochondrial; Nasopharyngeal carcinoma metastasis-related protein 1

Alternative UPACC:

Q9HD33; Q6XRG1; Q8N5D1

Background:

The Large ribosomal subunit protein uL29m, also known as 39S ribosomal protein L47, mitochondrial and Nasopharyngeal carcinoma metastasis-related protein 1, plays a crucial role in the mitochondrial ribosome. Its involvement in protein synthesis within mitochondria underscores its importance in cellular energy metabolism and overall cellular function.

Therapeutic significance:

Understanding the role of Large ribosomal subunit protein uL29m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a key target for research aimed at addressing mitochondrial disorders and enhancing cellular energy production.